Apollon Wealth Management LLC Acquires 5,393 Shares of Novo Nordisk A/S (NYSE:NVO)

Apollon Wealth Management LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 13.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,228 shares of the company’s stock after acquiring an additional 5,393 shares during the quarter. Apollon Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $3,804,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Pinnacle Bancorp Inc. lifted its holdings in Novo Nordisk A/S by 11.3% during the 3rd quarter. Pinnacle Bancorp Inc. now owns 1,160 shares of the company’s stock valued at $138,000 after purchasing an additional 118 shares during the last quarter. Contravisory Investment Management Inc. acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $163,000. JGP Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 18.6% in the third quarter. JGP Wealth Management LLC now owns 2,805 shares of the company’s stock valued at $334,000 after acquiring an additional 439 shares during the last quarter. Bennett Selby Investments LP grew its position in Novo Nordisk A/S by 11.1% during the 3rd quarter. Bennett Selby Investments LP now owns 26,151 shares of the company’s stock worth $3,114,000 after acquiring an additional 2,614 shares during the last quarter. Finally, Perfromance Wealth Partners LLC increased its holdings in Novo Nordisk A/S by 5.6% during the 3rd quarter. Perfromance Wealth Partners LLC now owns 159,137 shares of the company’s stock valued at $18,948,000 after purchasing an additional 8,419 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $86.39 on Friday. The stock’s 50-day simple moving average is $91.46 and its 200 day simple moving average is $111.51. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74. The company has a market cap of $387.66 billion, a P/E ratio of 26.26, a P/E/G ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 21.88%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.